STOCK TITAN

[4] – MAZELSKY JONATHAN JAY (CIK 0001556270)

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
4

DENTSPLY SIRONA (XRAY) director reported routine equity accruals. On 10/10/2025, the reporting person acquired 359.576 shares of common stock at $0 as dividend equivalents on previously granted RSUs. Following this transaction, directly held common stock totaled 28,451.376 shares.

The filing also shows an acquisition of 123.3618 units of phantom stock under the Directors' Deferred Compensation plan at a derivative price of $11.98. Phantom stock represents the economic equivalent of common stock and becomes payable in shares upon the director’s termination of service. After this accrual, the director held 11,743.5642 phantom stock units.

Notes clarify these were dividend-related accruals for RSUs and phantom stock, with RSUs converting to common stock on a 1:1 basis and phantom stock payable in common stock upon termination.

DENTSPLY SIRONA (XRAY) il direttore ha riportato accresciimenti azionari di routine. Il 10/10/2025 la persona che presenta la documentazione ha acquisito 359,576 azioni ordinarie a costo zero come equivalenti di dividendi su RSU precedentemente concessi. Dopo questa operazione, le azioni ordinarie detenute direttamente ammontavano a 28.451,376 azioni.

La pratica evidenzia inoltre l'acquisizione di 123,3618 unità di azioni fantasma nell'ambito del piano di compensazione differita dei direttori a un prezzo derivato di 11,98 $. Le azioni fantasma rappresentano l'equivalente economico delle azioni ordinarie e diventano pagabili in azioni al termine della rete di servizio del direttore. Dopo questa accumulazione, il direttore deteneva 11.743,5642 unità di azioni fantasma.

Le note chiariscono che si trattava di accresciamenti legati a dividendi per RSU e azioni fantasma, con le RSU che si convertono in azioni ordinarie su base 1:1 e le azioni fantasma pagabili in azioni ordinarie al termine.

El director de DENTSPLY SIRONA (XRAY) reportó acumulaciones de capital habituales. El 10/10/2025, la persona que presenta el informe adquirió 359.576 acciones comunes a costo cero como equivalentes de dividendos sobre RSU otorgadas previamente. Tras esta operación, las acciones comunes directamente mantenidas totalizaban 28.451,376 acciones.

La declaración también muestra la adquisición de 123,3618 unidades de acciones fantasma bajo el plan de Compensación Diferida de los Directores a un precio derivado de $11,98. Las acciones fantasma representan el equivalente económico de las acciones comunes y se vuelven pagaderas en acciones al finalizar el servicio del director. Tras esta acumulación, el director poseía 11.743,5642 unidades de acciones fantasma.

Las notas clarifican que se trató de acumulaciones relacionadas con dividendos para RSU y acciones fantasma, con las RSU convirtiéndose a acciones comunes en una base 1:1 y las acciones fantasma pagaderas en acciones comunes al terminar.

DENTSPLY SIRONA (XRAY) 이사는 일상적인 주식 누적을 보고했습니다. 2025년 10월 10일 보고자는 이전에 부여된 RSU에 대한 배당급여로 359.576주의 보통주를 무상 취득했습니다. 이 거래 이후 직접 보유한 보통주는 총 28,451.376주였습니다.

또한 이사회 연금 계획 하에 파생가격 $11.98로 팬텀 주식 123.3618단위를 취득한 것으로 공시되어 있습니다. 팬텀 주식은 보통주의 경제적 등가물이며 이사가 서비스 종료 시 주식으로 지급됩니다. 이 누적 후 이사는 팬텀 주식 11,743.5642단위를 보유하게 되었습니다.

주석은 이것이 RSU 및 팬텀 주식에 대한 배당 관련 누적임을 명확히 하며 RSU는 1:1로 보통주로 전환되고 팬텀 주식은 종료 시 보통주로 지급된다고 설명합니다.

DENTSPLY SIRONA (XRAY) le directeur a signalé des accruals d'actions ordinaires de routine. Le 10/10/2025, la personne déclarante a acquis 359,576 actions ordinaires à zéro dollar en tant qu'équivalents de dividendes sur des RSU accordées précédemment. Après cette transaction, les actions ordinaires détenues directement s'élevaient à 28 451,376 actions.

Le dossier montre également l'acquisition de 123,3618 unités d'actions fantômes dans le cadre du plan de rémunération différée des administrateurs à un prix dérivé de 11,98 $. Les actions fantômes représentent l'équivalent économique des actions ordinaires et deviennent payables en actions lors de la cessation du mandat du directeur. Après cet accrual, le directeur détenait 11 743,5642 unités d'actions fantômes.

Notes précisent qu'il s'agit d'accruals liés aux dividendes pour des RSU et des actions fantômes, les RSU se transformant en actions ordinaires sur une base 1:1 et les actions fantômes payables en actions ordinaires lors de la cessation.

DENTSPLY SIRONA (XRAY) Direktor meldete routinemäßige Eigenkapital-Akkumulationen. Am 10.10.2025 erwarb die meldende Person 359,576 Stammaktien zu 0 $ als Dividendenäquivalente auf zuvor gewährte RSUs. Nach dieser Transaktion belief sich die direkt gehaltenen Stammaktien auf 28.451,376 Aktien.

Die Einreichung zeigt außerdem den Erwerb von 123,3618 Einheiten Phantomaktien unter dem Directors' Deferred Compensation-Plan zu einem derivativen Preis von 11,98 $. Phantomaktien stellen das wirtschaftliche Äquivalent von Stammaktien dar und sind bei Beendigung der Dienstzeit des Direktors in Aktien zahlbar. Nach diesem Akkumulation hielt der Direktor 11.743,5642 Phantomaktieneinheiten.

Hinweise klären, dass es sich um dividendenauslösende Akkumulationen für RSUs und Phantomaktien handelt, wobei RSUs zu Stammaktien im Verhältnis 1:1 umgewandelt werden und Phantomaktien bei Beendigung in Stammaktien zahlbar sind.

قام مدير DENTSPLY SIRONA (XRAY) بالإبلاغ عن تراكمات الأسهم العادية الروتينية. في 10/10/2025، قامت الجهة المبلّغة بشراء 359.576 سهماً عادياً بدون تكلفة كمعادلات توزيعات على RSUs ممنوحة سابقاً. بعد هذه المعاملة، بلغ عدد الأسهم العادية المملوكة مباشرة 28.451,376 سهماً.

تظهر الإيداع أيضاً شراء 123.3618 وحدة من أسهم الشبح بموجب خطة التعويض المؤجل للمديرين بسعر مشتق قدره 11.98 دولار. تمثل أسهم الشبح المعادل الاقتصادي للأسهم العادية وتكون قابلة للدفع في الأسهم عند انتهاء خدمة المدير. بعد هذا التجميع، أصبح لدى المدير 11.743,5642 وحدة من أسهم الشبح.

توضح الملاحظات أن هذه هي تراكمات مرتبطة بتوزيعات RSU وأسهم الشبح، مع تحويل RSU إلى أسهم عادية بنسبة 1:1 وتسدّد أسهم الشبح في الأسهم العادية عند الانتهاء.

DENTSPLY SIRONA (XRAY) 的董事报告了例行的股权应计。 2025年10月10日,报告人以普通股0美元的分红等价物购买了359.576股,源自此前授予的RSU。在此交易之后,直接持有的普通股总数为28,451.376股。

备案还显示在董事延期补偿计划下以衍生价格11.98美元购买了123.3618单位的幻影股票。幻影股票代表普通股的经济等价物,董事服务终止时以股票形式支付。经此应计后,董事持有11,743.5642单位的幻影股票。

注释明确这些是与RSU和幻影股票相关的股息相关应计,RSU按1:1转换为普通股,幻影股票在终止时以普通股支付。

Positive
  • None.
Negative
  • None.

DENTSPLY SIRONA (XRAY) il direttore ha riportato accresciimenti azionari di routine. Il 10/10/2025 la persona che presenta la documentazione ha acquisito 359,576 azioni ordinarie a costo zero come equivalenti di dividendi su RSU precedentemente concessi. Dopo questa operazione, le azioni ordinarie detenute direttamente ammontavano a 28.451,376 azioni.

La pratica evidenzia inoltre l'acquisizione di 123,3618 unità di azioni fantasma nell'ambito del piano di compensazione differita dei direttori a un prezzo derivato di 11,98 $. Le azioni fantasma rappresentano l'equivalente economico delle azioni ordinarie e diventano pagabili in azioni al termine della rete di servizio del direttore. Dopo questa accumulazione, il direttore deteneva 11.743,5642 unità di azioni fantasma.

Le note chiariscono che si trattava di accresciamenti legati a dividendi per RSU e azioni fantasma, con le RSU che si convertono in azioni ordinarie su base 1:1 e le azioni fantasma pagabili in azioni ordinarie al termine.

El director de DENTSPLY SIRONA (XRAY) reportó acumulaciones de capital habituales. El 10/10/2025, la persona que presenta el informe adquirió 359.576 acciones comunes a costo cero como equivalentes de dividendos sobre RSU otorgadas previamente. Tras esta operación, las acciones comunes directamente mantenidas totalizaban 28.451,376 acciones.

La declaración también muestra la adquisición de 123,3618 unidades de acciones fantasma bajo el plan de Compensación Diferida de los Directores a un precio derivado de $11,98. Las acciones fantasma representan el equivalente económico de las acciones comunes y se vuelven pagaderas en acciones al finalizar el servicio del director. Tras esta acumulación, el director poseía 11.743,5642 unidades de acciones fantasma.

Las notas clarifican que se trató de acumulaciones relacionadas con dividendos para RSU y acciones fantasma, con las RSU convirtiéndose a acciones comunes en una base 1:1 y las acciones fantasma pagaderas en acciones comunes al terminar.

DENTSPLY SIRONA (XRAY) 이사는 일상적인 주식 누적을 보고했습니다. 2025년 10월 10일 보고자는 이전에 부여된 RSU에 대한 배당급여로 359.576주의 보통주를 무상 취득했습니다. 이 거래 이후 직접 보유한 보통주는 총 28,451.376주였습니다.

또한 이사회 연금 계획 하에 파생가격 $11.98로 팬텀 주식 123.3618단위를 취득한 것으로 공시되어 있습니다. 팬텀 주식은 보통주의 경제적 등가물이며 이사가 서비스 종료 시 주식으로 지급됩니다. 이 누적 후 이사는 팬텀 주식 11,743.5642단위를 보유하게 되었습니다.

주석은 이것이 RSU 및 팬텀 주식에 대한 배당 관련 누적임을 명확히 하며 RSU는 1:1로 보통주로 전환되고 팬텀 주식은 종료 시 보통주로 지급된다고 설명합니다.

DENTSPLY SIRONA (XRAY) le directeur a signalé des accruals d'actions ordinaires de routine. Le 10/10/2025, la personne déclarante a acquis 359,576 actions ordinaires à zéro dollar en tant qu'équivalents de dividendes sur des RSU accordées précédemment. Après cette transaction, les actions ordinaires détenues directement s'élevaient à 28 451,376 actions.

Le dossier montre également l'acquisition de 123,3618 unités d'actions fantômes dans le cadre du plan de rémunération différée des administrateurs à un prix dérivé de 11,98 $. Les actions fantômes représentent l'équivalent économique des actions ordinaires et deviennent payables en actions lors de la cessation du mandat du directeur. Après cet accrual, le directeur détenait 11 743,5642 unités d'actions fantômes.

Notes précisent qu'il s'agit d'accruals liés aux dividendes pour des RSU et des actions fantômes, les RSU se transformant en actions ordinaires sur une base 1:1 et les actions fantômes payables en actions ordinaires lors de la cessation.

DENTSPLY SIRONA (XRAY) Direktor meldete routinemäßige Eigenkapital-Akkumulationen. Am 10.10.2025 erwarb die meldende Person 359,576 Stammaktien zu 0 $ als Dividendenäquivalente auf zuvor gewährte RSUs. Nach dieser Transaktion belief sich die direkt gehaltenen Stammaktien auf 28.451,376 Aktien.

Die Einreichung zeigt außerdem den Erwerb von 123,3618 Einheiten Phantomaktien unter dem Directors' Deferred Compensation-Plan zu einem derivativen Preis von 11,98 $. Phantomaktien stellen das wirtschaftliche Äquivalent von Stammaktien dar und sind bei Beendigung der Dienstzeit des Direktors in Aktien zahlbar. Nach diesem Akkumulation hielt der Direktor 11.743,5642 Phantomaktieneinheiten.

Hinweise klären, dass es sich um dividendenauslösende Akkumulationen für RSUs und Phantomaktien handelt, wobei RSUs zu Stammaktien im Verhältnis 1:1 umgewandelt werden und Phantomaktien bei Beendigung in Stammaktien zahlbar sind.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
1. Name and Address of Reporting Person*
MAZELSKY JONATHAN JAY

(Last) (First) (Middle)
C/O DENTSPLY SIRONA INC
13320-B BALLANTYNE CORPORATE PLACE

(Street)
CHARLOTTE NC 28277

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
DENTSPLY SIRONA Inc. [ XRAY ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
10/10/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 10/10/2025 A 359.576(1) A $0 28,451.376 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Phantom Stock (Directors' Deferred Compensation) DDC (2) 10/10/2025 A 123.3618(3) (2) (2) Common Stock 123.3618 $11.98 11,743.5642 D
Explanation of Responses:
1. Represents dividends on restricted stock units (RSUs) awarded to the Reporting Person in the form of additional RSUs and are subject to the same vesting terms as the underlying awards. The dividends vest simultaneously with the RSUs to which they relate. Each RSU converts to common stock on a 1:1 basis.
2. Each share of phantom stock is the economic equivalent of one share of common stock. The shares of phantom stock become payable in common stock upon the reporting person's termination of service as a director.
3. Comprised of phantom stock acquired as a result of accrued dividends.
/s/ Jessica Nielsen Causey, Attorney-in-Fact for Jonathan Jay Mazelsky 10/15/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did DENTSPLY SIRONA (XRAY) disclose in this Form 4?

A director acquired 359.576 common shares at $0 from RSU dividend equivalents and 123.3618 phantom stock units tied to accrued dividends on 10/10/2025.

How many XRAY common shares does the director hold after the transaction?

The director beneficially owned 28,451.376 common shares directly after the reported transaction.

What is the director’s phantom stock balance after the transaction?

The director held 11,743.5642 phantom stock units after the acquisition.

What are RSU dividend equivalents mentioned for XRAY?

They are dividends on RSUs credited as additional RSUs, vesting on the same schedule as the underlying awards; each RSU converts 1:1 into common stock.

What is XRAY phantom stock and when is it payable?

Each unit is the economic equivalent of one share of common stock and becomes payable in common stock upon the director’s termination of service.

What were the transaction codes and prices reported?

Both entries were coded as A (acquired). Common shares were acquired at $0; the phantom stock derivative price was $11.98.
Dentsply Sirona Inc

NASDAQ:XRAY

XRAY Rankings

XRAY Latest News

XRAY Latest SEC Filings

XRAY Stock Data

2.52B
198.69M
0.39%
104.2%
3.83%
Medical Instruments & Supplies
Dental Equipment & Supplies
Link
United States
CHARLOTTE